Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467189 | 0.71 | HDAC1 (0.39) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL25361777 | 0.69 | PSMB8 (0.48) | HDAC1HDAC8HDAC6C3AR1ELANE | |
| SCHEMBL25361770 | 0.69 | PSMB8 (0.48) | HDAC1HDAC8HDAC6C3AR1ELANE | |
| SCHEMBL12522835 | 0.68 | C3AR1 (0.33) | C3AR1 | |
| SCHEMBL10025444 | 0.68 | HDAC1 (0.36) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL10025448 | 0.68 | HDAC1 (0.36) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL2535620 | 0.66 | ACACB (0.46) | — | |
| SCHEMBL25363892 | 0.66 | PSMB8 (0.45) | HDAC1HDAC8HDAC6C3AR1ELANE | |
| SCHEMBL25363889 | 0.66 | PSMB8 (0.45) | HDAC1HDAC8HDAC6C3AR1ELANE | |
| SCHEMBL22610053 | 0.64 | LONP1 (0.51) | AKR1B1HDAC1HDAC8HDAC6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | MCL1, MKI67, NCL | AKR1B1 799/4885HDAC1 114/4885HDAC8 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.